Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02272647 · ClinicalTrials.gov registry record · Phase 1
Progesterone Amplifies Estrogen-stimulated Growth Hormone Secretion in Older Women
A Phase 1 study of Healthy, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 47
- Enrollment target
- 1
- Study location
NCT02272647: Completed Phase 1 study of Healthy, sponsored by Mayo Clinic.
NCT02272647 is a Phase 1 study of Healthy that has completed, run by Mayo Clinic. The registered enrollment target is 47 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02272647, a Phase 1 study of Healthy, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 47 participants
- Enrollment target
- 1
- Study location
Study Summary
Progesterone amplifies estrogen-stimulated Growth Hormone (GH) secretion in postmenopausal women. Preliminary data are sought to estimate statistical power for more detailed studies of this hypothesis.
Conditions Studied
Interventions
- DRUG IM Saline Placebo (0.25 ml)
- DRUG IM Estradiol valerate (2.5 mg)
- DRUG IM Saline Placebo (0.5 ml)
- DRUG IM Estradiol valerate (5.0 mg)
- DRUG Oral Micronized Progesterone
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2014-12 |
| Est. Completion | 2018-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02272647
The ClinicalTrials.gov registry entry for NCT02272647 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (93% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 5 interventions - of which IM Saline Placebo (0.25 ml) is the first listed.
NCT02272647 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT02272647 about?
NCT02272647 is a clinical study titled "Progesterone Amplifies Estrogen-stimulated Growth Hormone Secretion in Older Women". Progesterone amplifies estrogen-stimulated Growth Hormone (GH) secretion in postmenopausal women. Preliminary data are sought to estimate statistical power for more detailed studies of this hypothesis.
What is the current status of trial NCT02272647?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 47 participants. The study started on 2014-12. Estimated completion is 2018-02.
What conditions does trial NCT02272647 study?
This clinical trial studies the following conditions: Healthy.
What interventions are being tested in trial NCT02272647?
The interventions under investigation include: IM Saline Placebo (0.25 ml) (DRUG), IM Estradiol valerate (2.5 mg) (DRUG), IM Saline Placebo (0.5 ml) (DRUG), IM Estradiol valerate (5.0 mg) (DRUG), Oral Micronized Progesterone (DRUG).
Who is sponsoring clinical trial NCT02272647?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02272647 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.
RECRUITING · Phase 1
-
A Study of LY3867070 in Healthy Participants
RECRUITING · Phase 1
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of AZD1613 in Healthy Participants.
RECRUITING · Phase 1
-
Evaluate the Pharmacokinetics, Safety, and Tolerability of NSHO-101 in Healthy Participants
RECRUITING · Phase 1
-
Comparison of the Short-Term Effect of Dietary Carbohydrate Restriction Versus Exogenous Ketone Supplementation on Myocardial Glucose Suppression and Timing to Achieve a State of Ketosis Using FDG PET/CT Serial Imaging
RECRUITING · Phase 1
-
A Study of V118E in Healthy Participants (V118E-003)
RECRUITING · Phase 1
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.